Strategic Pillar,Category,Strategic Goal,Strategic Program,Q1 Objective,Q2 Objective,Q3 Objective,Q4 Objective,ORD LT Sponsor(s),Sponsor(s)/Lead(s),Reporting owner(s),Q1 Status,Q2 Status,Q3 Status,Q4 Status,Q1 Comments,Q2 Comments,Q3 Comments,Q4 Comments
Precision Medicine,Biomarker Discovery,Validate novel predictive biomarkers,BD-01 Validate Initiative 1,"In Q1 we will launch the BD-01 Validate Initiative 1 project in support of the strategic goal to validate novel predictive biomarkers. This involves assembling the core team, finalizing the detailed project charter, and securing cross‑functional commitment. An early engagement with clinical teams will ensure downstream study readiness.",Achieve 50% of planned experiments for BD-01 Validate Initiative 1.,Complete data analysis phase of BD-01 Validate Initiative 1.,Submit year‑end review and next‑year plan for BD-01 Validate Initiative 1.,Dr. Alice Nguyen,Elijah Hernandez,Ethan Jackson,Green,,,,On track; milestones met.,,,
Precision Medicine,Biomarker Discovery,Validate novel predictive biomarkers,BD-02 Validate Initiative 2,"In Q1 we will launch the BD-02 Validate Initiative 2 project in support of the strategic goal to validate novel predictive biomarkers. Key deliverables include drafting protocols, outlining resource requirements, and obtaining governance approval. Vendor assessments will be completed to decide on any external partnerships needed.",Achieve 50% of planned experiments for BD-02 Validate Initiative 2.,Complete data analysis phase of BD-02 Validate Initiative 2.,Submit year‑end review and next‑year plan for BD-02 Validate Initiative 2.,Dr. Alice Nguyen,Noah Martin,Ethan Jackson,Green,,,,On track; milestones met.,,,
Precision Medicine,Biomarker Discovery,Validate novel predictive biomarkers,BD-03 Validate Initiative 3,"In Q1 we will launch the BD-03 Validate Initiative 3 project in support of the strategic goal to validate novel predictive biomarkers. Key deliverables include drafting protocols, outlining resource requirements, and obtaining governance approval. We will set up a dashboard to track milestones and provide transparent real‑time updates. By quarter close, we expect to have a resourced, scheduled, and risk‑assessed plan endorsed by sponsors.",Achieve 50% of planned experiments for BD-03 Validate Initiative 3.,Complete data analysis phase of BD-03 Validate Initiative 3.,Submit year‑end review and next‑year plan for BD-03 Validate Initiative 3.,Dr. Alice Nguyen,Henry Garcia,Sophia Jackson,Green,,,,On track; milestones met.,,,
Precision Medicine,Biomarker Discovery,Expand tumor genomics database,BD-04 Expand Initiative 4,"In Q1 we will launch the BD-04 Expand Initiative 4 project in support of the strategic goal to expand tumor genomics database. Key deliverables include drafting protocols, outlining resource requirements, and obtaining governance approval. We will set up a dashboard to track milestones and provide transparent real‑time updates. Our stretch goal is to initiate early pilot work so that data is available for Q2 decision gates.",Achieve 50% of planned experiments for BD-04 Expand Initiative 4.,Complete data analysis phase of BD-04 Expand Initiative 4.,Submit year‑end review and next‑year plan for BD-04 Expand Initiative 4.,Dr. Alice Nguyen,James Wilson,James Lopez,Amber,,,,Minor delays; mitigation plan in place.,,,
Precision Medicine,Biomarker Discovery,Expand tumor genomics database,BD-05 Expand Initiative 5,"In Q1 we will launch the BD-05 Expand Initiative 5 project in support of the strategic goal to expand tumor genomics database. This involves assembling the core team, finalizing the detailed project charter, and securing cross‑functional commitment. We will set up a dashboard to track milestones and provide transparent real‑time updates.",Achieve 50% of planned experiments for BD-05 Expand Initiative 5.,Complete data analysis phase of BD-05 Expand Initiative 5.,Submit year‑end review and next‑year plan for BD-05 Expand Initiative 5.,Dr. Alice Nguyen,Charlotte Lopez,James Lopez,Green,,,,On track; milestones met.,,,
Precision Medicine,Biomarker Discovery,Expand tumor genomics database,BD-06 Expand Initiative 6,"In Q1 we will launch the BD-06 Expand Initiative 6 project in support of the strategic goal to expand tumor genomics database. We will host a series of workshops to solidify scope, clarify success metrics, and map dependencies. Risks and mitigation strategies will be documented early to ensure the program remains on track.",Achieve 50% of planned experiments for BD-06 Expand Initiative 6.,Complete data analysis phase of BD-06 Expand Initiative 6.,Submit year‑end review and next‑year plan for BD-06 Expand Initiative 6.,Dr. Alice Nguyen,Henry Rodriguez,Isabella Anderson,Green,,,,On track; milestones met.,,,
Precision Medicine,Biomarker Discovery,Advance single‑cell analytics platform,BD-07 Advance Initiative 7,"In Q1 we will launch the BD-07 Advance Initiative 7 project in support of the strategic goal to advance single‑cell analytics platform. Key deliverables include drafting protocols, outlining resource requirements, and obtaining governance approval. Vendor assessments will be completed to decide on any external partnerships needed. Our stretch goal is to initiate early pilot work so that data is available for Q2 decision gates.",Achieve 50% of planned experiments for BD-07 Advance Initiative 7.,Complete data analysis phase of BD-07 Advance Initiative 7.,Submit year‑end review and next‑year plan for BD-07 Advance Initiative 7.,Dr. Alice Nguyen,Benjamin Smith,Jacob Brown,Green,,,,On track; milestones met.,,,
Precision Medicine,Biomarker Discovery,Advance single‑cell analytics platform,BD-08 Advance Initiative 8,"In Q1 we will launch the BD-08 Advance Initiative 8 project in support of the strategic goal to advance single‑cell analytics platform. Key deliverables include drafting protocols, outlining resource requirements, and obtaining governance approval. An early engagement with clinical teams will ensure downstream study readiness. Quarter‑end exit criteria include a locked protocol, budget sign‑off, and an agreed set of KPIs.",Achieve 50% of planned experiments for BD-08 Advance Initiative 8.,Complete data analysis phase of BD-08 Advance Initiative 8.,Submit year‑end review and next‑year plan for BD-08 Advance Initiative 8.,Dr. Alice Nguyen,Olivia Hernandez,Olivia Hernandez,Green,,,,On track; milestones met.,,,
Precision Medicine,Biomarker Discovery,Advance single‑cell analytics platform,BD-09 Advance Initiative 9,"In Q1 we will launch the BD-09 Advance Initiative 9 project in support of the strategic goal to advance single‑cell analytics platform. This involves assembling the core team, finalizing the detailed project charter, and securing cross‑functional commitment. We will set up a dashboard to track milestones and provide transparent real‑time updates. Quarter‑end exit criteria include a locked protocol, budget sign‑off, and an agreed set of KPIs.",Achieve 50% of planned experiments for BD-09 Advance Initiative 9.,Complete data analysis phase of BD-09 Advance Initiative 9.,Submit year‑end review and next‑year plan for BD-09 Advance Initiative 9.,Dr. Alice Nguyen,Benjamin Rodriguez,Olivia Hernandez,Amber,,,,Minor delays; mitigation plan in place.,,,
Precision Medicine,Targeted Therapies,Optimize next‑gen kinase inhibitors,TT-10 Optimize Initiative 10,In Q1 we will launch the TT-10 Optimize Initiative 10 project in support of the strategic goal to optimize next‑gen kinase inhibitors. The kick‑off will culminate in a signed execution plan and a communication roll‑out to all contributors. Risks and mitigation strategies will be documented early to ensure the program remains on track. Success for Q1 will be measured by completion of the scoped deliverables and endorsement from the Oncology R&D Leadership Team.,Achieve 50% of planned experiments for TT-10 Optimize Initiative 10.,Complete data analysis phase of TT-10 Optimize Initiative 10.,Submit year‑end review and next‑year plan for TT-10 Optimize Initiative 10.,Dr. Michael Rossi,Lucas Thomas,Charlotte Hernandez,Green,,,,On track; milestones met.,,,
Precision Medicine,Targeted Therapies,Optimize next‑gen kinase inhibitors,TT-11 Optimize Initiative 11,"In Q1 we will launch the TT-11 Optimize Initiative 11 project in support of the strategic goal to optimize next‑gen kinase inhibitors. We will host a series of workshops to solidify scope, clarify success metrics, and map dependencies. Initial experiments or data pulls will begin by the end of the quarter to validate feasibility. Quarter‑end exit criteria include a locked protocol, budget sign‑off, and an agreed set of KPIs.",Achieve 50% of planned experiments for TT-11 Optimize Initiative 11.,Complete data analysis phase of TT-11 Optimize Initiative 11.,Submit year‑end review and next‑year plan for TT-11 Optimize Initiative 11.,Dr. Michael Rossi,Jacob Martinez,Charlotte Hernandez,Red,,,,Significant risk; exec escalation.,,,
Precision Medicine,Targeted Therapies,Optimize next‑gen kinase inhibitors,TT-12 Optimize Initiative 12,"In Q1 we will launch the TT-12 Optimize Initiative 12 project in support of the strategic goal to optimize next‑gen kinase inhibitors. Our immediate focus will be to refine the scientific plan, align timelines with stakeholders, and allocate budget. Vendor assessments will be completed to decide on any external partnerships needed. By quarter close, we expect to have a resourced, scheduled, and risk‑assessed plan endorsed by sponsors.",Achieve 50% of planned experiments for TT-12 Optimize Initiative 12.,Complete data analysis phase of TT-12 Optimize Initiative 12.,Submit year‑end review and next‑year plan for TT-12 Optimize Initiative 12.,Dr. Michael Rossi,Abigail Martin,James Jackson,Green,,,,On track; milestones met.,,,
Precision Medicine,Targeted Therapies,Develop bispecific antibodies portfolio,TT-13 Develop Initiative 13,"In Q1 we will launch the TT-13 Develop Initiative 13 project in support of the strategic goal to develop bispecific antibodies portfolio. This involves assembling the core team, finalizing the detailed project charter, and securing cross‑functional commitment. Initial experiments or data pulls will begin by the end of the quarter to validate feasibility. Completion of training for all contributors is also targeted within this timeframe.",Achieve 50% of planned experiments for TT-13 Develop Initiative 13.,Complete data analysis phase of TT-13 Develop Initiative 13.,Submit year‑end review and next‑year plan for TT-13 Develop Initiative 13.,Dr. Michael Rossi,Mason Gonzalez,Emma Rodriguez,Red,,,,Significant risk; exec escalation.,,,
Precision Medicine,Targeted Therapies,Develop bispecific antibodies portfolio,TT-14 Develop Initiative 14,"In Q1 we will launch the TT-14 Develop Initiative 14 project in support of the strategic goal to develop bispecific antibodies portfolio. Key deliverables include drafting protocols, outlining resource requirements, and obtaining governance approval. Vendor assessments will be completed to decide on any external partnerships needed.",Achieve 50% of planned experiments for TT-14 Develop Initiative 14.,Complete data analysis phase of TT-14 Develop Initiative 14.,Submit year‑end review and next‑year plan for TT-14 Develop Initiative 14.,Dr. Michael Rossi,Charlotte Williams,Sophia Davis,Red,,,,Significant risk; exec escalation.,,,
Precision Medicine,Targeted Therapies,Develop bispecific antibodies portfolio,TT-15 Develop Initiative 15,"In Q1 we will launch the TT-15 Develop Initiative 15 project in support of the strategic goal to develop bispecific antibodies portfolio. Key deliverables include drafting protocols, outlining resource requirements, and obtaining governance approval. Vendor assessments will be completed to decide on any external partnerships needed. By quarter close, we expect to have a resourced, scheduled, and risk‑assessed plan endorsed by sponsors.",Achieve 50% of planned experiments for TT-15 Develop Initiative 15.,Complete data analysis phase of TT-15 Develop Initiative 15.,Submit year‑end review and next‑year plan for TT-15 Develop Initiative 15.,Dr. Michael Rossi,Jacob Miller,Emma Rodriguez,Red,,,,Significant risk; exec escalation.,,,
Precision Medicine,Targeted Therapies,Integrate AI for target selection,TT-16 Integrate Initiative 16,"In Q1 we will launch the TT-16 Integrate Initiative 16 project in support of the strategic goal to integrate ai for target selection. We will host a series of workshops to solidify scope, clarify success metrics, and map dependencies. Initial experiments or data pulls will begin by the end of the quarter to validate feasibility.",Achieve 50% of planned experiments for TT-16 Integrate Initiative 16.,Complete data analysis phase of TT-16 Integrate Initiative 16.,Submit year‑end review and next‑year plan for TT-16 Integrate Initiative 16.,Dr. Michael Rossi,Elijah Davis,Noah Davis,Green,,,,On track; milestones met.,,,
Precision Medicine,Targeted Therapies,Integrate AI for target selection,TT-17 Integrate Initiative 17,"In Q1 we will launch the TT-17 Integrate Initiative 17 project in support of the strategic goal to integrate ai for target selection. Key deliverables include drafting protocols, outlining resource requirements, and obtaining governance approval. Initial experiments or data pulls will begin by the end of the quarter to validate feasibility. Success for Q1 will be measured by completion of the scoped deliverables and endorsement from the Oncology R&D Leadership Team.",Achieve 50% of planned experiments for TT-17 Integrate Initiative 17.,Complete data analysis phase of TT-17 Integrate Initiative 17.,Submit year‑end review and next‑year plan for TT-17 Integrate Initiative 17.,Dr. Michael Rossi,Charlotte Anderson,Logan Garcia,Green,,,,On track; milestones met.,,,
Precision Medicine,Targeted Therapies,Integrate AI for target selection,TT-18 Integrate Initiative 18,"In Q1 we will launch the TT-18 Integrate Initiative 18 project in support of the strategic goal to integrate ai for target selection. We will host a series of workshops to solidify scope, clarify success metrics, and map dependencies. We will set up a dashboard to track milestones and provide transparent real‑time updates. Our stretch goal is to initiate early pilot work so that data is available for Q2 decision gates.",Achieve 50% of planned experiments for TT-18 Integrate Initiative 18.,Complete data analysis phase of TT-18 Integrate Initiative 18.,Submit year‑end review and next‑year plan for TT-18 Integrate Initiative 18.,Dr. Michael Rossi,Henry Jackson,Logan Garcia,Green,,,,On track; milestones met.,,,
Precision Medicine,Companion Diagnostics,Co‑develop CDx assays with therapy programs,CDX-19 Co‑develop Initiative 19,"In Q1 we will launch the CDX-19 Co‑develop Initiative 19 project in support of the strategic goal to co‑develop cdx assays with therapy programs. The kick‑off will culminate in a signed execution plan and a communication roll‑out to all contributors. Vendor assessments will be completed to decide on any external partnerships needed. Quarter‑end exit criteria include a locked protocol, budget sign‑off, and an agreed set of KPIs.",Achieve 50% of planned experiments for CDX-19 Co‑develop Initiative 19.,Complete data analysis phase of CDX-19 Co‑develop Initiative 19.,Submit year‑end review and next‑year plan for CDX-19 Co‑develop Initiative 19.,Dr. Priya Desai,Liam Gonzalez,Liam Brown,Green,,,,On track; milestones met.,,,
Precision Medicine,Companion Diagnostics,Co‑develop CDx assays with therapy programs,CDX-20 Co‑develop Initiative 20,"In Q1 we will launch the CDX-20 Co‑develop Initiative 20 project in support of the strategic goal to co‑develop cdx assays with therapy programs. This involves assembling the core team, finalizing the detailed project charter, and securing cross‑functional commitment. Initial experiments or data pulls will begin by the end of the quarter to validate feasibility.",Achieve 50% of planned experiments for CDX-20 Co‑develop Initiative 20.,Complete data analysis phase of CDX-20 Co‑develop Initiative 20.,Submit year‑end review and next‑year plan for CDX-20 Co‑develop Initiative 20.,Dr. Priya Desai,Henry Johnson,Mia Wilson,Green,,,,On track; milestones met.,,,
Precision Medicine,Companion Diagnostics,Co‑develop CDx assays with therapy programs,CDX-21 Co‑develop Initiative 21,"In Q1 we will launch the CDX-21 Co‑develop Initiative 21 project in support of the strategic goal to co‑develop cdx assays with therapy programs. Key deliverables include drafting protocols, outlining resource requirements, and obtaining governance approval. Vendor assessments will be completed to decide on any external partnerships needed.",Achieve 50% of planned experiments for CDX-21 Co‑develop Initiative 21.,Complete data analysis phase of CDX-21 Co‑develop Initiative 21.,Submit year‑end review and next‑year plan for CDX-21 Co‑develop Initiative 21.,Dr. Priya Desai,Harper Williams,Liam Brown,Green,,,,On track; milestones met.,,,
Precision Medicine,Companion Diagnostics,Obtain FDA clearance for NGS panel,CDX-22 Obtain Initiative 22,"In Q1 we will launch the CDX-22 Obtain Initiative 22 project in support of the strategic goal to obtain fda clearance for ngs panel. We will host a series of workshops to solidify scope, clarify success metrics, and map dependencies. Risks and mitigation strategies will be documented early to ensure the program remains on track.",Achieve 50% of planned experiments for CDX-22 Obtain Initiative 22.,Complete data analysis phase of CDX-22 Obtain Initiative 22.,Submit year‑end review and next‑year plan for CDX-22 Obtain Initiative 22.,Dr. Priya Desai,Elijah Anderson,Liam Jackson,Green,,,,On track; milestones met.,,,
Precision Medicine,Companion Diagnostics,Obtain FDA clearance for NGS panel,CDX-23 Obtain Initiative 23,"In Q1 we will launch the CDX-23 Obtain Initiative 23 project in support of the strategic goal to obtain fda clearance for ngs panel. Key deliverables include drafting protocols, outlining resource requirements, and obtaining governance approval. An early engagement with clinical teams will ensure downstream study readiness.",Achieve 50% of planned experiments for CDX-23 Obtain Initiative 23.,Complete data analysis phase of CDX-23 Obtain Initiative 23.,Submit year‑end review and next‑year plan for CDX-23 Obtain Initiative 23.,Dr. Priya Desai,Benjamin Martin,Ava Davis,Amber,,,,Minor delays; mitigation plan in place.,,,
Precision Medicine,Companion Diagnostics,Obtain FDA clearance for NGS panel,CDX-24 Obtain Initiative 24,"In Q1 we will launch the CDX-24 Obtain Initiative 24 project in support of the strategic goal to obtain fda clearance for ngs panel. Our immediate focus will be to refine the scientific plan, align timelines with stakeholders, and allocate budget. Risks and mitigation strategies will be documented early to ensure the program remains on track. Success for Q1 will be measured by completion of the scoped deliverables and endorsement from the Oncology R&D Leadership Team.",Achieve 50% of planned experiments for CDX-24 Obtain Initiative 24.,Complete data analysis phase of CDX-24 Obtain Initiative 24.,Submit year‑end review and next‑year plan for CDX-24 Obtain Initiative 24.,Dr. Priya Desai,Liam Thomas,Liam Jackson,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Early Clinical Development,Reduce IND cycle time by 20%,ECD-25 Reduce Initiative 25,"In Q1 we will launch the ECD-25 Reduce Initiative 25 project in support of the strategic goal to reduce ind cycle time by 20%. This involves assembling the core team, finalizing the detailed project charter, and securing cross‑functional commitment. Initial experiments or data pulls will begin by the end of the quarter to validate feasibility. Completion of training for all contributors is also targeted within this timeframe.",Achieve 50% of planned experiments for ECD-25 Reduce Initiative 25.,Complete data analysis phase of ECD-25 Reduce Initiative 25.,Submit year‑end review and next‑year plan for ECD-25 Reduce Initiative 25.,Dr. James Carter,Mason Anderson,Charlotte Moore,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Early Clinical Development,Reduce IND cycle time by 20%,ECD-26 Reduce Initiative 26,"In Q1 we will launch the ECD-26 Reduce Initiative 26 project in support of the strategic goal to reduce ind cycle time by 20%. We will host a series of workshops to solidify scope, clarify success metrics, and map dependencies. Vendor assessments will be completed to decide on any external partnerships needed. Quarter‑end exit criteria include a locked protocol, budget sign‑off, and an agreed set of KPIs.",Achieve 50% of planned experiments for ECD-26 Reduce Initiative 26.,Complete data analysis phase of ECD-26 Reduce Initiative 26.,Submit year‑end review and next‑year plan for ECD-26 Reduce Initiative 26.,Dr. James Carter,Ethan Miller,Charlotte Moore,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Early Clinical Development,Reduce IND cycle time by 20%,ECD-27 Reduce Initiative 27,"In Q1 we will launch the ECD-27 Reduce Initiative 27 project in support of the strategic goal to reduce ind cycle time by 20%. Our immediate focus will be to refine the scientific plan, align timelines with stakeholders, and allocate budget. Initial experiments or data pulls will begin by the end of the quarter to validate feasibility.",Achieve 50% of planned experiments for ECD-27 Reduce Initiative 27.,Complete data analysis phase of ECD-27 Reduce Initiative 27.,Submit year‑end review and next‑year plan for ECD-27 Reduce Initiative 27.,Dr. James Carter,Ava Smith,Jacob Williams,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Early Clinical Development,Reduce IND cycle time by 20%,ECD-28 Reduce Initiative 28,"In Q1 we will launch the ECD-28 Reduce Initiative 28 project in support of the strategic goal to reduce ind cycle time by 20%. Key deliverables include drafting protocols, outlining resource requirements, and obtaining governance approval. An early engagement with clinical teams will ensure downstream study readiness. Success for Q1 will be measured by completion of the scoped deliverables and endorsement from the Oncology R&D Leadership Team.",Achieve 50% of planned experiments for ECD-28 Reduce Initiative 28.,Complete data analysis phase of ECD-28 Reduce Initiative 28.,Submit year‑end review and next‑year plan for ECD-28 Reduce Initiative 28.,Dr. James Carter,Henry Wilson,Jacob Williams,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Early Clinical Development,Implement adaptive trial designs,ECD-29 Implement Initiative 29,"In Q1 we will launch the ECD-29 Implement Initiative 29 project in support of the strategic goal to implement adaptive trial designs. Our immediate focus will be to refine the scientific plan, align timelines with stakeholders, and allocate budget. Initial experiments or data pulls will begin by the end of the quarter to validate feasibility.",Achieve 50% of planned experiments for ECD-29 Implement Initiative 29.,Complete data analysis phase of ECD-29 Implement Initiative 29.,Submit year‑end review and next‑year plan for ECD-29 Implement Initiative 29.,Dr. James Carter,Emma Miller,Emma Brown,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Early Clinical Development,Implement adaptive trial designs,ECD-30 Implement Initiative 30,"In Q1 we will launch the ECD-30 Implement Initiative 30 project in support of the strategic goal to implement adaptive trial designs. This involves assembling the core team, finalizing the detailed project charter, and securing cross‑functional commitment. An early engagement with clinical teams will ensure downstream study readiness.",Achieve 50% of planned experiments for ECD-30 Implement Initiative 30.,Complete data analysis phase of ECD-30 Implement Initiative 30.,Submit year‑end review and next‑year plan for ECD-30 Implement Initiative 30.,Dr. James Carter,Emma Taylor,Emma Brown,Amber,,,,Minor delays; mitigation plan in place.,,,
Pipeline Acceleration,Early Clinical Development,Implement adaptive trial designs,ECD-31 Implement Initiative 31,"In Q1 we will launch the ECD-31 Implement Initiative 31 project in support of the strategic goal to implement adaptive trial designs. Key deliverables include drafting protocols, outlining resource requirements, and obtaining governance approval. Risks and mitigation strategies will be documented early to ensure the program remains on track. Quarter‑end exit criteria include a locked protocol, budget sign‑off, and an agreed set of KPIs.",Achieve 50% of planned experiments for ECD-31 Implement Initiative 31.,Complete data analysis phase of ECD-31 Implement Initiative 31.,Submit year‑end review and next‑year plan for ECD-31 Implement Initiative 31.,Dr. James Carter,Sophia Brown,Emma Brown,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Early Clinical Development,Expand first‑in‑human trial network,ECD-32 Expand Initiative 32,"In Q1 we will launch the ECD-32 Expand Initiative 32 project in support of the strategic goal to expand first‑in‑human trial network. Our immediate focus will be to refine the scientific plan, align timelines with stakeholders, and allocate budget. An early engagement with clinical teams will ensure downstream study readiness. Completion of training for all contributors is also targeted within this timeframe.",Achieve 50% of planned experiments for ECD-32 Expand Initiative 32.,Complete data analysis phase of ECD-32 Expand Initiative 32.,Submit year‑end review and next‑year plan for ECD-32 Expand Initiative 32.,Dr. James Carter,Mason Rodriguez,Jacob Jackson,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Early Clinical Development,Expand first‑in‑human trial network,ECD-33 Expand Initiative 33,"In Q1 we will launch the ECD-33 Expand Initiative 33 project in support of the strategic goal to expand first‑in‑human trial network. Key deliverables include drafting protocols, outlining resource requirements, and obtaining governance approval. An early engagement with clinical teams will ensure downstream study readiness. Completion of training for all contributors is also targeted within this timeframe.",Achieve 50% of planned experiments for ECD-33 Expand Initiative 33.,Complete data analysis phase of ECD-33 Expand Initiative 33.,Submit year‑end review and next‑year plan for ECD-33 Expand Initiative 33.,Dr. James Carter,Noah Thomas,Noah Gonzalez,Red,,,,Significant risk; exec escalation.,,,
Pipeline Acceleration,Early Clinical Development,Expand first‑in‑human trial network,ECD-34 Expand Initiative 34,"In Q1 we will launch the ECD-34 Expand Initiative 34 project in support of the strategic goal to expand first‑in‑human trial network. We will host a series of workshops to solidify scope, clarify success metrics, and map dependencies. Initial experiments or data pulls will begin by the end of the quarter to validate feasibility. Quarter‑end exit criteria include a locked protocol, budget sign‑off, and an agreed set of KPIs.",Achieve 50% of planned experiments for ECD-34 Expand Initiative 34.,Complete data analysis phase of ECD-34 Expand Initiative 34.,Submit year‑end review and next‑year plan for ECD-34 Expand Initiative 34.,Dr. James Carter,Charlotte Williams,Jacob Jackson,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Regulatory Affairs,Harmonize global filings,RA-35 Harmonize Initiative 35,In Q1 we will launch the RA-35 Harmonize Initiative 35 project in support of the strategic goal to harmonize global filings. The kick‑off will culminate in a signed execution plan and a communication roll‑out to all contributors. We will set up a dashboard to track milestones and provide transparent real‑time updates. Success for Q1 will be measured by completion of the scoped deliverables and endorsement from the Oncology R&D Leadership Team.,Achieve 50% of planned experiments for RA-35 Harmonize Initiative 35.,Complete data analysis phase of RA-35 Harmonize Initiative 35.,Submit year‑end review and next‑year plan for RA-35 Harmonize Initiative 35.,Dr. Sophia Hernandez,Isabella Anderson,Olivia Lopez,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Regulatory Affairs,Harmonize global filings,RA-36 Harmonize Initiative 36,"In Q1 we will launch the RA-36 Harmonize Initiative 36 project in support of the strategic goal to harmonize global filings. We will host a series of workshops to solidify scope, clarify success metrics, and map dependencies. Vendor assessments will be completed to decide on any external partnerships needed.",Achieve 50% of planned experiments for RA-36 Harmonize Initiative 36.,Complete data analysis phase of RA-36 Harmonize Initiative 36.,Submit year‑end review and next‑year plan for RA-36 Harmonize Initiative 36.,Dr. Sophia Hernandez,Isabella Jones,Noah Johnson,Amber,,,,Minor delays; mitigation plan in place.,,,
Pipeline Acceleration,Regulatory Affairs,Harmonize global filings,RA-37 Harmonize Initiative 37,"In Q1 we will launch the RA-37 Harmonize Initiative 37 project in support of the strategic goal to harmonize global filings. Key deliverables include drafting protocols, outlining resource requirements, and obtaining governance approval. An early engagement with clinical teams will ensure downstream study readiness.",Achieve 50% of planned experiments for RA-37 Harmonize Initiative 37.,Complete data analysis phase of RA-37 Harmonize Initiative 37.,Submit year‑end review and next‑year plan for RA-37 Harmonize Initiative 37.,Dr. Sophia Hernandez,Noah Jones,Noah Johnson,Amber,,,,Minor delays; mitigation plan in place.,,,
Pipeline Acceleration,Regulatory Affairs,Strengthen agency engagement strategy,RA-38 Strengthen Initiative 38,"In Q1 we will launch the RA-38 Strengthen Initiative 38 project in support of the strategic goal to strengthen agency engagement strategy. Our immediate focus will be to refine the scientific plan, align timelines with stakeholders, and allocate budget. Vendor assessments will be completed to decide on any external partnerships needed.",Achieve 50% of planned experiments for RA-38 Strengthen Initiative 38.,Complete data analysis phase of RA-38 Strengthen Initiative 38.,Submit year‑end review and next‑year plan for RA-38 Strengthen Initiative 38.,Dr. Sophia Hernandez,Emma Johnson,Jacob Smith,Amber,,,,Minor delays; mitigation plan in place.,,,
Pipeline Acceleration,Regulatory Affairs,Strengthen agency engagement strategy,RA-39 Strengthen Initiative 39,"In Q1 we will launch the RA-39 Strengthen Initiative 39 project in support of the strategic goal to strengthen agency engagement strategy. Key deliverables include drafting protocols, outlining resource requirements, and obtaining governance approval. Vendor assessments will be completed to decide on any external partnerships needed. Completion of training for all contributors is also targeted within this timeframe.",Achieve 50% of planned experiments for RA-39 Strengthen Initiative 39.,Complete data analysis phase of RA-39 Strengthen Initiative 39.,Submit year‑end review and next‑year plan for RA-39 Strengthen Initiative 39.,Dr. Sophia Hernandez,Sophia Rodriguez,Sophia Garcia,Amber,,,,Minor delays; mitigation plan in place.,,,
Pipeline Acceleration,Regulatory Affairs,Strengthen agency engagement strategy,RA-40 Strengthen Initiative 40,"In Q1 we will launch the RA-40 Strengthen Initiative 40 project in support of the strategic goal to strengthen agency engagement strategy. Our immediate focus will be to refine the scientific plan, align timelines with stakeholders, and allocate budget. Vendor assessments will be completed to decide on any external partnerships needed.",Achieve 50% of planned experiments for RA-40 Strengthen Initiative 40.,Complete data analysis phase of RA-40 Strengthen Initiative 40.,Submit year‑end review and next‑year plan for RA-40 Strengthen Initiative 40.,Dr. Sophia Hernandez,Logan Jackson,Jacob Smith,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Regulatory Affairs,Strengthen agency engagement strategy,RA-41 Strengthen Initiative 41,"In Q1 we will launch the RA-41 Strengthen Initiative 41 project in support of the strategic goal to strengthen agency engagement strategy. This involves assembling the core team, finalizing the detailed project charter, and securing cross‑functional commitment. Vendor assessments will be completed to decide on any external partnerships needed. Our stretch goal is to initiate early pilot work so that data is available for Q2 decision gates.",Achieve 50% of planned experiments for RA-41 Strengthen Initiative 41.,Complete data analysis phase of RA-41 Strengthen Initiative 41.,Submit year‑end review and next‑year plan for RA-41 Strengthen Initiative 41.,Dr. Sophia Hernandez,Jacob Thomas,Sophia Garcia,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Regulatory Affairs,Enhance CMC readiness,RA-42 Enhance Initiative 42,"In Q1 we will launch the RA-42 Enhance Initiative 42 project in support of the strategic goal to enhance cmc readiness. This involves assembling the core team, finalizing the detailed project charter, and securing cross‑functional commitment. An early engagement with clinical teams will ensure downstream study readiness. Quarter‑end exit criteria include a locked protocol, budget sign‑off, and an agreed set of KPIs.",Achieve 50% of planned experiments for RA-42 Enhance Initiative 42.,Complete data analysis phase of RA-42 Enhance Initiative 42.,Submit year‑end review and next‑year plan for RA-42 Enhance Initiative 42.,Dr. Sophia Hernandez,Charlotte Wilson,Sophia Johnson,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Regulatory Affairs,Enhance CMC readiness,RA-43 Enhance Initiative 43,"In Q1 we will launch the RA-43 Enhance Initiative 43 project in support of the strategic goal to enhance cmc readiness. We will host a series of workshops to solidify scope, clarify success metrics, and map dependencies. Vendor assessments will be completed to decide on any external partnerships needed.",Achieve 50% of planned experiments for RA-43 Enhance Initiative 43.,Complete data analysis phase of RA-43 Enhance Initiative 43.,Submit year‑end review and next‑year plan for RA-43 Enhance Initiative 43.,Dr. Sophia Hernandez,Benjamin Garcia,Noah Thomas,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Regulatory Affairs,Enhance CMC readiness,RA-44 Enhance Initiative 44,"In Q1 we will launch the RA-44 Enhance Initiative 44 project in support of the strategic goal to enhance cmc readiness. This involves assembling the core team, finalizing the detailed project charter, and securing cross‑functional commitment. An early engagement with clinical teams will ensure downstream study readiness.",Achieve 50% of planned experiments for RA-44 Enhance Initiative 44.,Complete data analysis phase of RA-44 Enhance Initiative 44.,Submit year‑end review and next‑year plan for RA-44 Enhance Initiative 44.,Dr. Sophia Hernandez,Amelia Jackson,Sophia Johnson,Amber,,,,Minor delays; mitigation plan in place.,,,
Pipeline Acceleration,Digital Trial Innovation,Deploy decentralized trial platform,DTI-45 Deploy Initiative 45,"In Q1 we will launch the DTI-45 Deploy Initiative 45 project in support of the strategic goal to deploy decentralized trial platform. This involves assembling the core team, finalizing the detailed project charter, and securing cross‑functional commitment. Vendor assessments will be completed to decide on any external partnerships needed. Success for Q1 will be measured by completion of the scoped deliverables and endorsement from the Oncology R&D Leadership Team.",Achieve 50% of planned experiments for DTI-45 Deploy Initiative 45.,Complete data analysis phase of DTI-45 Deploy Initiative 45.,Submit year‑end review and next‑year plan for DTI-45 Deploy Initiative 45.,Dr. Wei Zhang,Emma Jones,Henry Smith,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Digital Trial Innovation,Deploy decentralized trial platform,DTI-46 Deploy Initiative 46,"In Q1 we will launch the DTI-46 Deploy Initiative 46 project in support of the strategic goal to deploy decentralized trial platform. This involves assembling the core team, finalizing the detailed project charter, and securing cross‑functional commitment. An early engagement with clinical teams will ensure downstream study readiness. Quarter‑end exit criteria include a locked protocol, budget sign‑off, and an agreed set of KPIs.",Achieve 50% of planned experiments for DTI-46 Deploy Initiative 46.,Complete data analysis phase of DTI-46 Deploy Initiative 46.,Submit year‑end review and next‑year plan for DTI-46 Deploy Initiative 46.,Dr. Wei Zhang,Isabella Hernandez,Benjamin Wilson,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Digital Trial Innovation,Deploy decentralized trial platform,DTI-47 Deploy Initiative 47,"In Q1 we will launch the DTI-47 Deploy Initiative 47 project in support of the strategic goal to deploy decentralized trial platform. Our immediate focus will be to refine the scientific plan, align timelines with stakeholders, and allocate budget. We will set up a dashboard to track milestones and provide transparent real‑time updates. Completion of training for all contributors is also targeted within this timeframe.",Achieve 50% of planned experiments for DTI-47 Deploy Initiative 47.,Complete data analysis phase of DTI-47 Deploy Initiative 47.,Submit year‑end review and next‑year plan for DTI-47 Deploy Initiative 47.,Dr. Wei Zhang,Logan Williams,Benjamin Wilson,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Digital Trial Innovation,Leverage wearables for safety monitoring,DTI-48 Leverage Initiative 48,"In Q1 we will launch the DTI-48 Leverage Initiative 48 project in support of the strategic goal to leverage wearables for safety monitoring. Our immediate focus will be to refine the scientific plan, align timelines with stakeholders, and allocate budget. We will set up a dashboard to track milestones and provide transparent real‑time updates. Our stretch goal is to initiate early pilot work so that data is available for Q2 decision gates.",Achieve 50% of planned experiments for DTI-48 Leverage Initiative 48.,Complete data analysis phase of DTI-48 Leverage Initiative 48.,Submit year‑end review and next‑year plan for DTI-48 Leverage Initiative 48.,Dr. Wei Zhang,Jacob Johnson,Jacob Brown,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Digital Trial Innovation,Leverage wearables for safety monitoring,DTI-49 Leverage Initiative 49,"In Q1 we will launch the DTI-49 Leverage Initiative 49 project in support of the strategic goal to leverage wearables for safety monitoring. Our immediate focus will be to refine the scientific plan, align timelines with stakeholders, and allocate budget. Vendor assessments will be completed to decide on any external partnerships needed. Our stretch goal is to initiate early pilot work so that data is available for Q2 decision gates.",Achieve 50% of planned experiments for DTI-49 Leverage Initiative 49.,Complete data analysis phase of DTI-49 Leverage Initiative 49.,Submit year‑end review and next‑year plan for DTI-49 Leverage Initiative 49.,Dr. Wei Zhang,Isabella Garcia,Jacob Brown,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Digital Trial Innovation,Leverage wearables for safety monitoring,DTI-50 Leverage Initiative 50,"In Q1 we will launch the DTI-50 Leverage Initiative 50 project in support of the strategic goal to leverage wearables for safety monitoring. We will host a series of workshops to solidify scope, clarify success metrics, and map dependencies. We will set up a dashboard to track milestones and provide transparent real‑time updates. By quarter close, we expect to have a resourced, scheduled, and risk‑assessed plan endorsed by sponsors.",Achieve 50% of planned experiments for DTI-50 Leverage Initiative 50.,Complete data analysis phase of DTI-50 Leverage Initiative 50.,Submit year‑end review and next‑year plan for DTI-50 Leverage Initiative 50.,Dr. Wei Zhang,Abigail Martinez,Isabella Williams,Amber,,,,Minor delays; mitigation plan in place.,,,
Pipeline Acceleration,Digital Trial Innovation,Leverage wearables for safety monitoring,DTI-51 Leverage Initiative 51,"In Q1 we will launch the DTI-51 Leverage Initiative 51 project in support of the strategic goal to leverage wearables for safety monitoring. The kick‑off will culminate in a signed execution plan and a communication roll‑out to all contributors. Initial experiments or data pulls will begin by the end of the quarter to validate feasibility. By quarter close, we expect to have a resourced, scheduled, and risk‑assessed plan endorsed by sponsors.",Achieve 50% of planned experiments for DTI-51 Leverage Initiative 51.,Complete data analysis phase of DTI-51 Leverage Initiative 51.,Submit year‑end review and next‑year plan for DTI-51 Leverage Initiative 51.,Dr. Wei Zhang,Amelia Moore,Jacob Brown,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Digital Trial Innovation,Automate data capture workflows,DTI-52 Automate Initiative 52,"In Q1 we will launch the DTI-52 Automate Initiative 52 project in support of the strategic goal to automate data capture workflows. We will host a series of workshops to solidify scope, clarify success metrics, and map dependencies. Initial experiments or data pulls will begin by the end of the quarter to validate feasibility.",Achieve 50% of planned experiments for DTI-52 Automate Initiative 52.,Complete data analysis phase of DTI-52 Automate Initiative 52.,Submit year‑end review and next‑year plan for DTI-52 Automate Initiative 52.,Dr. Wei Zhang,Mason Brown,Charlotte Martinez,Green,,,,On track; milestones met.,,,
Pipeline Acceleration,Digital Trial Innovation,Automate data capture workflows,DTI-53 Automate Initiative 53,"In Q1 we will launch the DTI-53 Automate Initiative 53 project in support of the strategic goal to automate data capture workflows. We will host a series of workshops to solidify scope, clarify success metrics, and map dependencies. Vendor assessments will be completed to decide on any external partnerships needed.",Achieve 50% of planned experiments for DTI-53 Automate Initiative 53.,Complete data analysis phase of DTI-53 Automate Initiative 53.,Submit year‑end review and next‑year plan for DTI-53 Automate Initiative 53.,Dr. Wei Zhang,Lucas Johnson,Charlotte Martinez,Red,,,,Significant risk; exec escalation.,,,
Pipeline Acceleration,Digital Trial Innovation,Automate data capture workflows,DTI-54 Automate Initiative 54,"In Q1 we will launch the DTI-54 Automate Initiative 54 project in support of the strategic goal to automate data capture workflows. We will host a series of workshops to solidify scope, clarify success metrics, and map dependencies. We will set up a dashboard to track milestones and provide transparent real‑time updates.",Achieve 50% of planned experiments for DTI-54 Automate Initiative 54.,Complete data analysis phase of DTI-54 Automate Initiative 54.,Submit year‑end review and next‑year plan for DTI-54 Automate Initiative 54.,Dr. Wei Zhang,Elijah Taylor,Lucas Williams,Amber,,,,Minor delays; mitigation plan in place.,,,
Pipeline Acceleration,Digital Trial Innovation,Automate data capture workflows,DTI-55 Automate Initiative 55,"In Q1 we will launch the DTI-55 Automate Initiative 55 project in support of the strategic goal to automate data capture workflows. We will host a series of workshops to solidify scope, clarify success metrics, and map dependencies. We will set up a dashboard to track milestones and provide transparent real‑time updates.",Achieve 50% of planned experiments for DTI-55 Automate Initiative 55.,Complete data analysis phase of DTI-55 Automate Initiative 55.,Submit year‑end review and next‑year plan for DTI-55 Automate Initiative 55.,Dr. Wei Zhang,Mason Gonzalez,Charlotte Martinez,Green,,,,On track; milestones met.,,,
Patient Engagement,Real‑World Evidence,Build oncology RWE registry,RWE-56 Build Initiative 56,"In Q1 we will launch the RWE-56 Build Initiative 56 project in support of the strategic goal to build oncology rwe registry. This involves assembling the core team, finalizing the detailed project charter, and securing cross‑functional commitment. Vendor assessments will be completed to decide on any external partnerships needed. Success for Q1 will be measured by completion of the scoped deliverables and endorsement from the Oncology R&D Leadership Team.",Achieve 50% of planned experiments for RWE-56 Build Initiative 56.,Complete data analysis phase of RWE-56 Build Initiative 56.,Submit year‑end review and next‑year plan for RWE-56 Build Initiative 56.,Dr. Karen Johnson,Mason Wilson,Logan Wilson,Amber,,,,Minor delays; mitigation plan in place.,,,
Patient Engagement,Real‑World Evidence,Build oncology RWE registry,RWE-57 Build Initiative 57,"In Q1 we will launch the RWE-57 Build Initiative 57 project in support of the strategic goal to build oncology rwe registry. Key deliverables include drafting protocols, outlining resource requirements, and obtaining governance approval. Initial experiments or data pulls will begin by the end of the quarter to validate feasibility. By quarter close, we expect to have a resourced, scheduled, and risk‑assessed plan endorsed by sponsors.",Achieve 50% of planned experiments for RWE-57 Build Initiative 57.,Complete data analysis phase of RWE-57 Build Initiative 57.,Submit year‑end review and next‑year plan for RWE-57 Build Initiative 57.,Dr. Karen Johnson,Noah Moore,Elijah Johnson,Amber,,,,Minor delays; mitigation plan in place.,,,
Patient Engagement,Real‑World Evidence,Build oncology RWE registry,RWE-58 Build Initiative 58,"In Q1 we will launch the RWE-58 Build Initiative 58 project in support of the strategic goal to build oncology rwe registry. Key deliverables include drafting protocols, outlining resource requirements, and obtaining governance approval. An early engagement with clinical teams will ensure downstream study readiness. Success for Q1 will be measured by completion of the scoped deliverables and endorsement from the Oncology R&D Leadership Team.",Achieve 50% of planned experiments for RWE-58 Build Initiative 58.,Complete data analysis phase of RWE-58 Build Initiative 58.,Submit year‑end review and next‑year plan for RWE-58 Build Initiative 58.,Dr. Karen Johnson,James Hernandez,Elijah Johnson,Green,,,,On track; milestones met.,,,
Patient Engagement,Real‑World Evidence,Generate comparative effectiveness studies,RWE-59 Generate Initiative 59,In Q1 we will launch the RWE-59 Generate Initiative 59 project in support of the strategic goal to generate comparative effectiveness studies. The kick‑off will culminate in a signed execution plan and a communication roll‑out to all contributors. Initial experiments or data pulls will begin by the end of the quarter to validate feasibility.,Achieve 50% of planned experiments for RWE-59 Generate Initiative 59.,Complete data analysis phase of RWE-59 Generate Initiative 59.,Submit year‑end review and next‑year plan for RWE-59 Generate Initiative 59.,Dr. Karen Johnson,Noah Thomas,Evelyn Anderson,Green,,,,On track; milestones met.,,,
Patient Engagement,Real‑World Evidence,Generate comparative effectiveness studies,RWE-60 Generate Initiative 60,"In Q1 we will launch the RWE-60 Generate Initiative 60 project in support of the strategic goal to generate comparative effectiveness studies. Our immediate focus will be to refine the scientific plan, align timelines with stakeholders, and allocate budget. Vendor assessments will be completed to decide on any external partnerships needed. Completion of training for all contributors is also targeted within this timeframe.",Achieve 50% of planned experiments for RWE-60 Generate Initiative 60.,Complete data analysis phase of RWE-60 Generate Initiative 60.,Submit year‑end review and next‑year plan for RWE-60 Generate Initiative 60.,Dr. Karen Johnson,James Wilson,Evelyn Anderson,Green,,,,On track; milestones met.,,,
Patient Engagement,Real‑World Evidence,Generate comparative effectiveness studies,RWE-61 Generate Initiative 61,In Q1 we will launch the RWE-61 Generate Initiative 61 project in support of the strategic goal to generate comparative effectiveness studies. The kick‑off will culminate in a signed execution plan and a communication roll‑out to all contributors. Vendor assessments will be completed to decide on any external partnerships needed.,Achieve 50% of planned experiments for RWE-61 Generate Initiative 61.,Complete data analysis phase of RWE-61 Generate Initiative 61.,Submit year‑end review and next‑year plan for RWE-61 Generate Initiative 61.,Dr. Karen Johnson,Mason Hernandez,Evelyn Anderson,Green,,,,On track; milestones met.,,,
Patient Engagement,Real‑World Evidence,Integrate EHR data for signal detection,RWE-62 Integrate Initiative 62,"In Q1 we will launch the RWE-62 Integrate Initiative 62 project in support of the strategic goal to integrate ehr data for signal detection. We will host a series of workshops to solidify scope, clarify success metrics, and map dependencies. Initial experiments or data pulls will begin by the end of the quarter to validate feasibility.",Achieve 50% of planned experiments for RWE-62 Integrate Initiative 62.,Complete data analysis phase of RWE-62 Integrate Initiative 62.,Submit year‑end review and next‑year plan for RWE-62 Integrate Initiative 62.,Dr. Karen Johnson,Elijah Jackson,Sophia Rodriguez,Amber,,,,Minor delays; mitigation plan in place.,,,
Patient Engagement,Real‑World Evidence,Integrate EHR data for signal detection,RWE-63 Integrate Initiative 63,"In Q1 we will launch the RWE-63 Integrate Initiative 63 project in support of the strategic goal to integrate ehr data for signal detection. Key deliverables include drafting protocols, outlining resource requirements, and obtaining governance approval. Initial experiments or data pulls will begin by the end of the quarter to validate feasibility. Success for Q1 will be measured by completion of the scoped deliverables and endorsement from the Oncology R&D Leadership Team.",Achieve 50% of planned experiments for RWE-63 Integrate Initiative 63.,Complete data analysis phase of RWE-63 Integrate Initiative 63.,Submit year‑end review and next‑year plan for RWE-63 Integrate Initiative 63.,Dr. Karen Johnson,Charlotte Williams,Noah Gonzalez,Green,,,,On track; milestones met.,,,
Patient Engagement,Real‑World Evidence,Integrate EHR data for signal detection,RWE-64 Integrate Initiative 64,"In Q1 we will launch the RWE-64 Integrate Initiative 64 project in support of the strategic goal to integrate ehr data for signal detection. This involves assembling the core team, finalizing the detailed project charter, and securing cross‑functional commitment. We will set up a dashboard to track milestones and provide transparent real‑time updates. Quarter‑end exit criteria include a locked protocol, budget sign‑off, and an agreed set of KPIs.",Achieve 50% of planned experiments for RWE-64 Integrate Initiative 64.,Complete data analysis phase of RWE-64 Integrate Initiative 64.,Submit year‑end review and next‑year plan for RWE-64 Integrate Initiative 64.,Dr. Karen Johnson,Olivia Miller,Noah Gonzalez,Green,,,,On track; milestones met.,,,
Patient Engagement,Access & Equity,Increase minority patient enrollment,AE-65 Increase Initiative 65,"In Q1 we will launch the AE-65 Increase Initiative 65 project in support of the strategic goal to increase minority patient enrollment. This involves assembling the core team, finalizing the detailed project charter, and securing cross‑functional commitment. We will set up a dashboard to track milestones and provide transparent real‑time updates. Our stretch goal is to initiate early pilot work so that data is available for Q2 decision gates.",Achieve 50% of planned experiments for AE-65 Increase Initiative 65.,Complete data analysis phase of AE-65 Increase Initiative 65.,Submit year‑end review and next‑year plan for AE-65 Increase Initiative 65.,Dr. David Lee,Liam Gonzalez,Logan Thomas,Green,,,,On track; milestones met.,,,
Patient Engagement,Access & Equity,Increase minority patient enrollment,AE-66 Increase Initiative 66,"In Q1 we will launch the AE-66 Increase Initiative 66 project in support of the strategic goal to increase minority patient enrollment. Key deliverables include drafting protocols, outlining resource requirements, and obtaining governance approval. An early engagement with clinical teams will ensure downstream study readiness. By quarter close, we expect to have a resourced, scheduled, and risk‑assessed plan endorsed by sponsors.",Achieve 50% of planned experiments for AE-66 Increase Initiative 66.,Complete data analysis phase of AE-66 Increase Initiative 66.,Submit year‑end review and next‑year plan for AE-66 Increase Initiative 66.,Dr. David Lee,Noah Gonzalez,Abigail Garcia,Green,,,,On track; milestones met.,,,
Patient Engagement,Access & Equity,Increase minority patient enrollment,AE-67 Increase Initiative 67,"In Q1 we will launch the AE-67 Increase Initiative 67 project in support of the strategic goal to increase minority patient enrollment. We will host a series of workshops to solidify scope, clarify success metrics, and map dependencies. We will set up a dashboard to track milestones and provide transparent real‑time updates. Success for Q1 will be measured by completion of the scoped deliverables and endorsement from the Oncology R&D Leadership Team.",Achieve 50% of planned experiments for AE-67 Increase Initiative 67.,Complete data analysis phase of AE-67 Increase Initiative 67.,Submit year‑end review and next‑year plan for AE-67 Increase Initiative 67.,Dr. David Lee,Harper Thomas,Logan Thomas,Green,,,,On track; milestones met.,,,
Patient Engagement,Access & Equity,Implement financial assistance programs,AE-68 Implement Initiative 68,In Q1 we will launch the AE-68 Implement Initiative 68 project in support of the strategic goal to implement financial assistance programs. The kick‑off will culminate in a signed execution plan and a communication roll‑out to all contributors. Risks and mitigation strategies will be documented early to ensure the program remains on track.,Achieve 50% of planned experiments for AE-68 Implement Initiative 68.,Complete data analysis phase of AE-68 Implement Initiative 68.,Submit year‑end review and next‑year plan for AE-68 Implement Initiative 68.,Dr. David Lee,Ethan Williams,Liam Garcia,Green,,,,On track; milestones met.,,,
Patient Engagement,Access & Equity,Implement financial assistance programs,AE-69 Implement Initiative 69,"In Q1 we will launch the AE-69 Implement Initiative 69 project in support of the strategic goal to implement financial assistance programs. Our immediate focus will be to refine the scientific plan, align timelines with stakeholders, and allocate budget. An early engagement with clinical teams will ensure downstream study readiness. Quarter‑end exit criteria include a locked protocol, budget sign‑off, and an agreed set of KPIs.",Achieve 50% of planned experiments for AE-69 Implement Initiative 69.,Complete data analysis phase of AE-69 Implement Initiative 69.,Submit year‑end review and next‑year plan for AE-69 Implement Initiative 69.,Dr. David Lee,Lucas Rodriguez,Henry Miller,Green,,,,On track; milestones met.,,,
Patient Engagement,Access & Equity,Implement financial assistance programs,AE-70 Implement Initiative 70,"In Q1 we will launch the AE-70 Implement Initiative 70 project in support of the strategic goal to implement financial assistance programs. Our immediate focus will be to refine the scientific plan, align timelines with stakeholders, and allocate budget. Risks and mitigation strategies will be documented early to ensure the program remains on track.",Achieve 50% of planned experiments for AE-70 Implement Initiative 70.,Complete data analysis phase of AE-70 Implement Initiative 70.,Submit year‑end review and next‑year plan for AE-70 Implement Initiative 70.,Dr. David Lee,Ethan Miller,Liam Garcia,Green,,,,On track; milestones met.,,,
